Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Western Sahara Health Bulletin.
Press releases published on October 10, 2025
Bluejay Diagnostics Announces Closing of $4.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
ACTON, Mass., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing near-patient solutions for critical care, today announced the closing of its previously …
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of …
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today …
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on October 6, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non- …
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million
SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and …
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults.1 UZEDY (risperidone) extended- …
A Wake-Up Call for Parents, Doctors & Policy Makers, "An Inconvenient Study" shines a light on one of the most important questions of our time: Why Are So Many Of Our Kids Sick?
LOS ANGELES, Oct. 10, 2025 (GLOBE NEWSWIRE) -- In 2016, journalist Del Bigtree issued a challenge to the head of infectious disease at one of the most prestigious medical institutions in the world: conduct the most thorough vaxxed vs. unvaxxed study that …
Global Protein Drugs Market to Reach $655.7 Billion by 2029
Boston, Oct. 10, 2025 (GLOBE NEWSWIRE) -- As demand for targeted, biologic-based treatments continues to grow, protein drugs are transforming how pharmaceutical companies address chronic, genetic, and life-threatening diseases. From monoclonal antibodies ( …
RTOERO awards $104,000 in grants to boost local projects
Toronto, Ontario, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Community-building projects take many forms, but all help to contribute to a better quality of life. To add to that, RTOERO (soon to be Entente Education Canada) is supporting 26 local initiatives in …
Ergodyne Unveils New Winter Gear to Help Outdoor Workers Outlast Harsh Conditions
St. Paul, MN, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Ergodyne has announced the launch of its latest line of winter work gear, a collection designed to help workers prepare for and withstand the season’s most challenging conditions. The launch comes as the …
AB Science today reports its revenues for the first half of 2025 and provides an update on its activities
PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2025 AND KEY EVENTS DURING THE PERIOD Financial and corporate situation Operating deficit reduced by 24% compared to the first half of 2024, amounting to €2.7 million as …
AB Science annonce aujourd’hui ses résultats financiers semestriels au 30 juin 2025 et présente un point sur ses activités
COMMUNIQUE DE PRESSE AB SCIENCE PRÉSENTE SES RÉSULTATS FINANCIERS AU PREMIER SEMESTRE 2025 ET LES EVENEMENTS CLEFS DE LA PERIODE Situation financière et corporate Réduction du déficit opérationnel de 24% par rapport au premier semestre 2024, s’ …
Press release: Transparency Notification from Shareholder
Transparency Notification from Shareholder Ghent, Belgium – 10 October 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure …
Dua Lipa, Drag Icons, Diplo and Celebrities Headline MISTR’s National PrEP Day Kickoff
West Hollywood, Ca, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Last night, MISTR lit up The Abbey in West Hollywood to launch the inaugural National PrEP Day with a star-powered Blue Carpet Countdown event. Today, October 10, marks the first-ever National PrEP Day, …
Priovant’s Brepocitinib Poised to Address Steroid-Sparing Gap in Dermatomyositis as Rheumatologists Anticipate 2026 Launch
EXTON, PA, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Rheumatologists are eagerly anticipating the potential approval of brepocitinib, Priovant Therapeutics’ dual TYK2/JAK1 inhibitor, as a near-term advance for dermatomyositis (DM). According to Spherix Global …
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million
ASHBURN, Va., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has entered into a …
Zacks Small-Cap Research Initiates Coverage on NewGen
BANGKOK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”), a tech-forward, diversified, multi-jurisdictional high-growth entity transforming industries through innovative solutions across real estate …
WORK Medical Technology Group LTD Granted Additional 180-Day Period to Regain Nasdaq Compliance
Hangzhou, China, Oct. 10, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and …
YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities
Taipei, Taiwan, Oct. 10, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that its …